Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Emma Falling IversenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Itzayana G MillerDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Ole SøgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Ali DaneshDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Brad R JonesDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Funding
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Immunologic control of HIV-1 through combination bNAbs and biologics.U01AI145921 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2019 to 2024
$8.5M
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistenceR01MH130197 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI Lishomwa C Ndhlovu, Afamefuna Okoye · 2022 to 2026
$5.1M
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIVR01AI170239 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rachel Lena Rutishauser · 2022 to 2026
$4.0M
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirsR01AI147845 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI IRVINE, DARRELL J, JONES, R. BRAD · 2019 to 2023
$4.0M
Understanding Immune Evasion by HIV-1 RepliclonesR01AI165031 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HALVAS, ELIAS K. · 2021 to 2025
$3.6M
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational ApproachR01AI176601 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI R. Brad Jones, Neville Sanjana · 2023 to 2026
$3.3M
Deciphering Mechanisms of HIV Latency Reversal in Perinatal InfectionsR01AI150412 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PERSAUD, DEBORAH · 2020 to 2023
$3.1M
Mechanisms of CTL Resistance in HIV ReservoirsR01AI170245 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2022 to 2025
$3.0M
Defining and then Maximizing the Footprint of CTL Selection on HIV Integration Site Landscapes to Optimize Cure StrategiesR37AI181626 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Frederic D Bushman, R. Brad Jones · 2024 to 2026
$2.5M
Weill Cornell Initiative for Maximizing Student DevelopmentR25GM130494 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CARRASCO, YAZMIN PAULINA, CESARMAN, ETHEL · 2019 to 2023
Human immunodeficiency virus (HIV) remains a global health challenge with major research efforts being directed toward the unmet needs for a vaccine and a safe and scalable cure. Antiretroviral therapy (ART) suppresses viral replication but does not cure infection and so requires lifelong adherence. HIV-specific CD8+ T-cell responses play a crucial role in long-term HIV control as demonstrated in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Participant-Derived Xenograft Mouse Model to Decode Autologous Mechanisms of HIV Control and Evaluate Immunotherapies. · full record | OpenQuestion